Written answers
Tuesday, 5 November 2019
Department of Health
Generic Drugs Substitution
Alan Kelly (Tipperary, Labour)
Link to this: Individually | In context | Oireachtas source
442. To ask the Minister for Health the volume of uptake of biosimilar prescribing under the best value biologic process by the HSE to date in 2019; the number of patients prescribed biosimilars by treatment type to date in 2019; the average savings per patient compared to the originator drugs; and if he will make a statement on the matter. [44252/19]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
As this is an operational matter it has been referred to the Health Service Executive for direct reply to the Deputy.
Alan Kelly (Tipperary, Labour)
Link to this: Individually | In context | Oireachtas source
443. To ask the Minister for Health if the HSE has under the best value biologic process set targets for biosimilar uptake across the designated treatment areas; if so, the targets for 2019 and 2020 in terms of both volume of prescriptions and the share of biosimilar prescriptions versus originator subscriptions for the designated treatment areas; and if he will make a statement on the matter. [44253/19]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
As this is an operational matter it has been referred to the Health Service Executive for direct reply to the Deputy.
No comments